The national health surveillance agency (Anvisa) granted the record to the medicine trimetazidine dihydrochloride, indicated for the treatment of ischemic heart disease. This is the 29th generic drug unprecedented that had application accepted this year. With this publication the Agency exceeds the number of previously unpublished records published since 2011.
Giro News
Related products
News Item translated automatically
Click HERE to see original